In the phase 1/2 LIBRETTO-001 trial, the selective RET inhibitor selpercatinib demonstrated a favorable response rate and improved progression-free survival (PFS) in RET mutation-positive MTC or fusion-positive thyroid cancers.12 The gene discussed is RET; the disease is thyroid cancer.